Stock LAURUSLABS LAURUS LABS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Laurus Labs Limited

Equities

LAURUSLABS

INE947Q01028

Pharmaceuticals

Market Closed - NSE India S.E.
Other stock markets
 07:43:55 2024-06-28 EDT 		5-day change 1st Jan Change
424.6 INR +0.25% Intraday chart for Laurus Labs Limited -1.27% -1.31%
06-26 Willow Biosciences Provides Corporate Update and Signs New Partnered Program MT
06-26 Willow Biosciences Brief: Announced multi-product development and licensing partnership with Laurus Labs for manufacturing active pharmaceutical ingredients MT

Valuation

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026 2027
Capitalization 1 34,726 194,250 317,096 157,798 211,463 228,900 - -
Enterprise Value (EV) 1 44,264 208,321 333,657 177,033 235,117 251,041 250,591 248,564
P/E ratio 13.6 x 19.8 x 38.4 x 20 x 132 x 55.3 x 33 x 26.2 x
Yield 0.77% 0.55% 0.34% 0.68% 0.51% 0.34% 0.42% 0.45%
Capitalization / Revenue 1.23 x 4.04 x 6.42 x 2.61 x 4.2 x 3.89 x 3.35 x 3.09 x
EV / Revenue 1.56 x 4.33 x 6.76 x 2.93 x 4.66 x 4.26 x 3.67 x 3.35 x
EV / EBITDA 7.84 x 13.4 x 23.5 x 11.1 x 30.2 x 21.9 x 16.1 x 13.9 x
EV / FCF 35.3 x 424 x 974 x 4,733 x -1,863 x 68.7 x 105 x 49.7 x
FCF Yield 2.83% 0.24% 0.1% 0.02% -0.05% 1.45% 0.96% 2.01%
Price to Book 1.96 x 15 x 9.49 x 3.91 x 5.16 x 5.03 x 4.4 x 3.79 x
Nbr of stocks (in thousands) 534,572 536,602 537,359 538,651 538,966 539,159 - -
Reference price 2 64.96 362.0 590.1 293.0 392.4 424.6 424.6 424.6
Announcement Date 20-04-30 21-04-29 22-04-28 23-04-27 24-04-25 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026 2027
Net sales 1 28,317 48,135 49,356 60,406 50,408 58,887 68,285 74,100
EBITDA 1 5,645 15,507 14,224 15,922 7,775 11,454 15,558 17,839
EBIT 1 3,773 13,456 11,709 12,681 3,929 7,169 10,961 12,366
Operating Margin 13.32% 27.95% 23.72% 20.99% 7.79% 12.17% 16.05% 16.69%
Earnings before Tax (EBT) 1 2,936 13,011 10,838 11,089 2,364 5,897 9,833 11,871
Net income 1 2,553 9,836 8,275 7,901 1,606 4,315 7,231 8,818
Net margin 9.01% 20.43% 16.77% 13.08% 3.18% 7.33% 10.59% 11.9%
EPS 2 4.786 18.28 15.35 14.64 2.970 7.680 12.87 16.22
Free Cash Flow 1 1,254 491.2 342.6 37.4 -126.2 3,653 2,397 5,000
FCF margin 4.43% 1.02% 0.69% 0.06% -0.25% 6.2% 3.51% 6.75%
FCF Conversion (EBITDA) 22.21% 3.17% 2.41% 0.23% - 31.89% 15.41% 28.03%
FCF Conversion (Net income) 49.12% 4.99% 4.14% 0.47% - 84.66% 33.15% 56.7%
Dividend per Share 2 0.5000 2.000 2.000 2.000 2.000 1.450 1.767 1.900
Announcement Date 20-04-30 21-04-29 22-04-28 23-04-27 24-04-25 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3 2025 Q4
Net sales 1 10,288 14,248 15,389 15,759 15,448 13,809 11,818 12,244 11,949 14,397 13,502 13,870 13,939 15,122
EBITDA 2,853 3,967 4,542 4,489 4,036 2,855 1,667 1,879 1,814 2,415 - - - -
EBIT 1 2,213 3,310 3,834 3,671 3,191 1,985 761.7 945 830.1 1,392 1,418 1,491 1,429 1,852
Operating Margin 21.51% 23.23% 24.91% 23.29% 20.66% 14.38% 6.45% 7.72% 6.95% 9.67% 10.5% 10.75% 10.25% 12.25%
Earnings before Tax (EBT) 2,035 3,017 3,559 3,281 2,778 1,471 405.8 538.9 346.2 1,073 - - - -
Net income 1,550 2,305 2,513 2,328 2,030 1,030 248.5 369.5 231.4 756.1 - - - -
Net margin 15.06% 16.18% 16.33% 14.77% 13.14% 7.46% 2.1% 3.02% 1.94% 5.25% - - - -
EPS 2.850 4.280 4.660 4.320 3.760 1.900 0.4600 0.6800 0.4300 1.400 - - - -
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 22-01-27 22-04-28 22-07-27 22-10-21 23-01-30 23-04-27 23-07-27 23-10-20 24-01-24 24-04-25 - - - -
1INR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026 2027
Net Debt 1 9,538 14,071 16,561 19,235 23,654 22,141 21,691 19,664
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.69 x 0.9074 x 1.164 x 1.208 x 3.042 x 1.933 x 1.394 x 1.102 x
Free Cash Flow 1 1,254 491 343 37.4 -126 3,653 2,397 5,000
ROE (net income / shareholders' equity) 15.3% 45% 27.8% 21.4% 3.94% 9.72% 14.7% 15.2%
ROA (Net income/ Total Assets) - - 13% 10.8% 2% 5% 8% 10%
Assets 1 - - 63,594 73,142 80,239 86,291 90,386 88,182
Book Value Per Share 2 33.10 24.20 62.20 75.00 76.00 84.40 96.40 112.0
Cash Flow per Share - - - - - - - -
Capex 1 2,220 6,839 8,768 9,902 6,783 7,296 6,966 7,330
Capex / Sales 7.84% 14.21% 17.77% 16.39% 13.46% 12.39% 10.2% 9.89%
Announcement Date 20-04-30 21-04-29 22-04-28 23-04-27 24-04-25 - - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Laurus Labs Limited

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
15
Last Close Price
424.6 INR
Average target price
393.4 INR
Spread / Average Target
-7.34%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
LAURUS LABS LIMITED Stock Laurus Labs Limited
-1.31% 2.75B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.32% 815B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+44.05% 641B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.75% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+13.56% 314B
ABBVIE INC. Stock AbbVie Inc.
+10.68% 303B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.57% 242B
NOVARTIS AG Stock Novartis AG
+13.31% 218B
AMGEN INC. Stock Amgen Inc.
+8.48% 168B
PFIZER, INC. Stock Pfizer, Inc.
-2.81% 159B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. LAURUSLABS Stock
  4. Financials Laurus Labs Limited